Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A).

Jacky BP, Garay PE, Dupuy J, Nelson JB, Cai B, Molina Y, Wang J, Steward LE, Broide RS, Francis J, Aoki KR, Stevens RC, Fernández-Salas E.

PLoS Pathog. 2013;9(5):e1003369. doi: 10.1371/journal.ppat.1003369. Epub 2013 May 16.

2.

Control of autophagosome axonal retrograde flux by presynaptic activity unveiled using botulinum neurotoxin type a.

Wang T, Martin S, Papadopulos A, Harper CB, Mavlyutov TA, Niranjan D, Glass NR, Cooper-White JJ, Sibarita JB, Choquet D, Davletov B, Meunier FA.

J Neurosci. 2015 Apr 15;35(15):6179-94. doi: 10.1523/JNEUROSCI.3757-14.2015.

4.

Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A.

Benoit RM, Frey D, Hilbert M, Kevenaar JT, Wieser MM, Stirnimann CU, McMillan D, Ceska T, Lebon F, Jaussi R, Steinmetz MO, Schertler GF, Hoogenraad CC, Capitani G, Kammerer RA.

Nature. 2014 Jan 2;505(7481):108-11. doi: 10.1038/nature12732. Epub 2013 Nov 17.

PMID:
24240280
5.

Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F.

Fu Z, Chen C, Barbieri JT, Kim JJ, Baldwin MR.

Biochemistry. 2009 Jun 23;48(24):5631-41. doi: 10.1021/bi9002138.

6.

The C terminus of SNAP25 is essential for Ca(2+)-dependent binding of synaptotagmin to SNARE complexes.

Gerona RR, Larsen EC, Kowalchyk JA, Martin TF.

J Biol Chem. 2000 Mar 3;275(9):6328-36.

7.

Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A.

Ho M, Goh CH, Brothers MC, Wang S, Young RL, Ou Y, Lui JN, Kalafatis M, Lan X, Wolf AE, Rienstra CM, Wilson BA.

Protein Sci. 2012 Mar;21(3):318-26. doi: 10.1002/pro.2017.

8.

Uptake of botulinum neurotoxin into cultured neurons.

Keller JE, Cai F, Neale EA.

Biochemistry. 2004 Jan 20;43(2):526-32.

PMID:
14717608
9.

Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.

Wang J, Zurawski TH, Bodeker MO, Meng J, Boddul S, Aoki KR, Dolly JO.

Biochem J. 2012 May 15;444(1):59-67. doi: 10.1042/BJ20120100.

PMID:
22360156
10.

Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system.

Tsai YC, Maditz R, Kuo CL, Fishman PS, Shoemaker CB, Oyler GA, Weissman AM.

Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16554-9. doi: 10.1073/pnas.1008302107. Epub 2010 Sep 7.

11.

A Highly Specific Monoclonal Antibody for Botulinum Neurotoxin Type A-Cleaved SNAP25.

Rhéaume C, Cai BB, Wang J, Fernández-Salas E, Aoki KR, Francis J, Broide RS.

Toxins (Basel). 2015 Jun 24;7(7):2354-70. doi: 10.3390/toxins7072354.

12.

Botulinum neurotoxin serotype C associates with dual ganglioside receptors to facilitate cell entry.

Karalewitz AP, Fu Z, Baldwin MR, Kim JJ, Barbieri JT.

J Biol Chem. 2012 Nov 23;287(48):40806-16. doi: 10.1074/jbc.M112.404244. Epub 2012 Oct 1.

13.

Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.

Höltje M, Schulze S, Strotmeier J, Mahrhold S, Richter K, Binz T, Bigalke H, Ahnert-Hilger G, Rummel A.

Toxicon. 2013 Dec 1;75:108-21. doi: 10.1016/j.toxicon.2013.06.010. Epub 2013 Jun 29.

PMID:
23817019
14.

Long-distance retrograde effects of botulinum neurotoxin A.

Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M.

J Neurosci. 2008 Apr 2;28(14):3689-96. doi: 10.1523/JNEUROSCI.0375-08.2008.

15.

The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane.

Muraro L, Tosatto S, Motterlini L, Rossetto O, Montecucco C.

Biochem Biophys Res Commun. 2009 Feb 27;380(1):76-80. doi: 10.1016/j.bbrc.2009.01.037. Epub 2009 Jan 20.

PMID:
19161982
16.

Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.

Dolly JO, Wang J, Zurawski TH, Meng J.

FEBS J. 2011 Dec;278(23):4454-66. doi: 10.1111/j.1742-4658.2011.08205.x. Epub 2011 Jul 5.

17.

Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A.

Pellett S, Tepp WH, Stanker LH, Band PA, Johnson EA, Ichtchenko K.

Biochem Biophys Res Commun. 2011 Feb 25;405(4):673-7. doi: 10.1016/j.bbrc.2011.01.093. Epub 2011 Feb 1.

18.

Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

Peng L, Tepp WH, Johnson EA, Dong M.

PLoS Pathog. 2011 Mar;7(3):e1002008. doi: 10.1371/journal.ppat.1002008. Epub 2011 Mar 31.

19.

Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity.

Rummel A.

Curr Top Microbiol Immunol. 2013;364:61-90. doi: 10.1007/978-3-642-33570-9_4.

PMID:
23239349
20.

A yeast assay probes the interaction between botulinum neurotoxin serotype B and its SNARE substrate.

Fang H, Luo W, Henkel J, Barbieri J, Green N.

Proc Natl Acad Sci U S A. 2006 May 2;103(18):6958-63. Epub 2006 Apr 24.

Supplemental Content

Support Center